田口 和明 (タグチ カズアキ)

Taguchi, Kazuaki

写真a

所属(所属キャンパス)

薬学部 薬学科 薬効解析学講座 (芝共立)

職名

専任講師

経歴 【 表示 / 非表示

  • 2010年04月
    -
    2011年03月

    日本学術振興会特別研究員

  • 2011年04月
    -
    2013年03月

    熊本大学医学部附属病院, 薬剤部, 薬剤師

  • 2013年04月
    -
    2017年03月

    崇城大学 , 薬学部, 助教

  • 2018年04月
    -
    継続中

    慶應義塾大学, 薬学部, 専任講師

学歴 【 表示 / 非表示

  • 2006年03月

    熊本大学, 薬学部

    大学, 卒業

  • 2008年03月

    熊本大学

    大学院, 修了, 博士前期

  • 2011年03月

    熊本大学

    大学院, 修了, 博士後期

学位 【 表示 / 非表示

  • 博士 (薬学), 熊本大学, 2011年03月

免許・資格 【 表示 / 非表示

  • 薬剤師, 2006年04月

 
 

著書 【 表示 / 非表示

  • DDS先端技術の製剤への応用開発

    宗慶太郎, 田口和明, 技術情報協会, 2017年

    担当範囲: 第6章6節 pp. 360-8

  • Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses

    Taguchi K, Chuang VT, Yamasaki K, Otagiri M., Nova Science Publishers, Inc., 2015年

    担当範囲: Chapter 4, pp. 69-89

  • HUMAN SERUM ALBUMIN

    Taguchi K, Chuang VT, Otagiri M., 2013年

    担当範囲: Chapter 20, pp. 401-15

  • Acute Phase Proteins

    Taguchi K, Nishi K, Chuang VT, Maruyama T, Otagiri M., Intech, 2013年

    担当範囲: Chapter 6, pp.139-62

論文 【 表示 / 非表示

  • Cell uptake and anti-tumor effect of liposomes containing encapsulated paclitaxel-bound albumin against breast cancer cells in 2D and 3D cultured models

    Okamoto Y., Taguchi K., Imoto S., Giam Chuang V., Yamasaki K., Otagiri M.

    Journal of Drug Delivery Science and Technology (Journal of Drug Delivery Science and Technology)  55 2020年02月

    ISSN  17732247

     概要を見る

    © 2019 Elsevier B.V. Paclitaxel (PTX), a water insoluble anticancer drug, was incorporated into the inner aqueous core of a liposome without the aid of an organic co-solvent, via non-covalent binding with bovine serum albumin (BSA) to form a PTX-BSA liposome. In the present study, PTX-BSA-liposomes are shown to have potent effects on human-derived breast cancer cell lines, MCF-7 cells and MDA-MB-231 cells, in 2D monolayer cultured cells and 3D multicellular tumor spheroids. The results of cellular uptake studies in 2D monolayer cultured cells clearly showed that the fluorescence derived from dansyl-L-asparagine (DNSA), a model encapsulated drug, and Cy5-cholesterol (a model membrane) of DNSA-BSA-liposome were observed inside the cells. Along with cell uptake, the PTX-BSA-liposomes exhibited a concentration-dependent cytotoxicity against MCF-7 and MDA-MB-231 cells but the IC50 value of the PTX-BSA-liposomes was higher than that of free PTX and nab-PTX (albumin-bound PTX nanoparticle). On the other hand, PTX-BSA-liposome, as in the cases of free PTX and nab-PTX, inhibited cell growth in both 3D MCF-7 and MDA-MB-231 tumor spheroids, indicating that PTX-BSA-liposomes penetrated into the tumor spheroid. These results suggest that PTX-BSA-liposomes are an organic solvent free PTX formulation that would have potent anti-proliferative effects against breast cancer.

  • Enhanced dissolution and oral bioavailability of praziquantel by emulsification with human serum albumin followed by spray drying

    Yamasaki K., Taguchi K., Nishi K., Otagiri M., Seo H.

    European Journal of Pharmaceutical Sciences (European Journal of Pharmaceutical Sciences)  139 2019年11月

    ISSN  09280987

     概要を見る

    © 2019 Elsevier B.V. The goal of this study was to enhance the oral bioavailability of praziquantel through its conjugation with human serum albumin (HSA). Praziquantel-HSA particles were produced by spray drying an emulsion of an aqueous solution of HSA and a solution of praziquantel in oil. The particles were agglomerates of multiple smooth corrugated particles containing amorphous praziquantel nearly equivalent to the theoretical doses. The solubility of praziquantel in an aqueous medium was enhanced in both the produced particles and the physical mixture. In addition, the dissolution rate in an aqueous medium was enhanced in the case of particles, but not in a physical mixture. Thus, the inclusion of HSA by emulsification followed by spray drying appeared to contribute to the enhanced dissolution rate. In a pharmacokinetic study, the maximum plasma concentration (Cmax) and the area under the concentration-time curve (AUC) for the produced particles (HSA/praziquantel = 1/1 w/w) were approximately two times higher than the corresponding values for raw praziquantel. This increased oral bioavailability of the particles was considered to be due to the enhanced dissolution rate. This process for producing praziquantel-HSA particles could be useful in terms of improving the oral bioavailability of the other hydrophobic drugs.

  • Evaluation for optimal dosing of vancomycin in patients with different physical types

    Hashimoto M., Iketani O., Ichinose N., Enoki Y., Taguchi K., Uno S., Uwamino Y., Hasegawa N., Matsumoto K.

    Journal of Infection and Chemotherapy (Journal of Infection and Chemotherapy)  25 ( 9 ) 735 - 737 2019年09月

    共著,  ISSN  1341321X

     概要を見る

    © 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases The sufficient dose to obtain an optimal trough concentration of vancomycin (VCM) in patients with non-standard physical types remains controversial. In this study, we examined the relationship between the dose and physical type in patients in whom an optimal trough concentration was obtained among VCM-treated patients. We retrospectively investigated the dose of VCM and physical type in patients treated with VCM between January 2012 and January 2017 at two medical institutions (n = 272). The physical type was classified using the body mass index (BMI). Patients with a BMI of <18.5 kg/m2 were assigned to the lean group, those with a BMI of 18.5–24.9 kg/m2 were assigned to the standard group, and those with a BMI of ≥25 kg/m2 were assigned to the obesity group. The mean doses of VCM per time (mg/kg) to achieve the target trough concentration of VCM, 15–20 μg/mL, were 19.8 ± 4.3, 16.5 ± 3.7, and 13.7 ± 2.7 mg/kg in the lean, standard, and obesity groups, respectively. The dose per time to achieve the target trough concentration decreased significantly in association with an increase of BMI. The upper limit of the recommended dose (15–20 mg/kg) or higher in lean patients, and the lower dose in obese patients than the recommended dose might be appropriate to achieve the target trough concentration when we calculated the dose per time based on actual body weight.

  • Investigation of anti-tumor effect of doxorubicin-loaded human serum albumin nanoparticles prepared by a desolvation technique

    Kimura K., Yamasaki K., Nishi K., Taguchi K., Otagiri M.

    Cancer Chemotherapy and Pharmacology (Cancer Chemotherapy and Pharmacology)  83 ( 6 ) 1113 - 1120 2019年06月

    研究論文(学術雑誌), 共著, 査読有り,  ISSN  03445704

     概要を見る

    © 2019, Springer-Verlag GmbH Germany, part of Springer Nature. Purpose: Nanoparticles of human serum albumin (HSA) prepared using a desolvation method possess sizes suitable for tumor accumulation. Here, we report on an investigation of the anti-tumor effects and biodistribution of doxorubicin–HSA nanoparticles in vitro and in vivo. Methods: The cytotoxicity of nanoparticles was evaluated in 2D and 3D colon 26 cell cultures. Furthermore, the biodistribution and the anti-tumor activity of nanoparticles in colon 26-bearing mice were investigated. Assessments on the effect on metastasis and the toxicity were also carried out. Results: Doxorubicin–HSA nanoparticles showed cytotoxicity in colon 26 cancer cell cultures, although the cytotoxicity was less in the case of nanoparticles than in free doxorubicin. In vivo anti-tumor activity was more pronounced in nanoparticles despite the fact that their accumulation in tumors was not superior to that of free doxorubicin, suggesting that factors other than accumulation contribute to the enhanced anti-tumor activity of these nanoparticles. The administration of nanoparticles also resulted in the suppression of metastasis. Conclusions: The prepared nanoparticles appear to be effective for cancer therapy although further studies will be needed to clarify the details of anti-tumor activity and the toxicity of these nanoparticles.

  • Preparation, Characterization, and in Vitro/in Vivo Evaluation of Paclitaxel-Bound Albumin-Encapsulated Liposomes for the Treatment of Pancreatic Cancer

    Okamoto Y., Taguchi K., Sakuragi M., Imoto S., Yamasaki K., Otagiri M.

    ACS Omega (ACS Omega)  4 ( 5 ) 8693 - 8700 2019年05月

    研究論文(学術雑誌), 共著, 査読有り

     概要を見る

    © 2019 American Chemical Society. Paclitaxel (PTX)-loaded liposomes were developed with the goal of enhancing the effects of cancer treatment. Although loading substances into the lipid membrane of liposome cause some destabilization of the lipid membrane, PTX was nearly exclusively embedded in the lipid membrane of liposomes, due to its low water solubility. Hydrophobic drugs can be encapsulated into the inner core of bovine serum albumin (BSA)-encapsulated liposomes (BSA-liposome) via noncovalent binding to albumin. Since PTX is able to noncovalently bind to albumin, we attempted to prepare PTX-loaded BSA-liposome (PTX-BSA-liposome). The amount of PTX loaded in the BSA-liposome could be increased substantially by using ethanol, since ethanol increases PTX solubility in BSA solutions via prompting the binding PTX to BSA. On the basis of the results of transmission electron microscopy and small-angle X-ray scattering, PTX-BSA-liposome formed unilamellar vesicles that were spherical in shape and the PTX was encapsulated into the inner aqueous core of the liposome as a form of PTX-BSA complex. In addition, the PTX-BSA-liposome, as well as nab-PTX, showed cytotoxicity against human pancreatic cancer cells, AsPC-1 cells, in a PTX concentration-dependent manner. The in vivo antitumor effect of PTX-BSA-liposomes was also observed in a mouse model that had been subcutaneously inoculated with pancreatic cancer cells by virtue of its high accumulation at the tumor site via the enhanced permeability retention effect. These results suggest that PTX-BSA-liposomes have the potential for serving as a novel PTX preparation method for the treatment of pancreatic cancer.

全件表示 >>

総説・解説等 【 表示 / 非表示

  • Use of hemoglobin for delivering exogenous carbon monoxide in medicinal applications.

    Taguchi K,, Maruyama T,, Otagiri M.

     2019年

    総説・解説(学術雑誌), 共著

  • 細胞型人工赤血球の動態特性解析に基づく安全性評価と医療ガスデリバリーへの応用

    田口 和明

    薬学雑誌 138   1381 - 1389 2018年

    総説・解説(学術雑誌), 単著

  • The use of Hemoglobin vesicles for delivering medicinal gas for the treatment of intractable disorders.

    Taguchi K, Yamasaki K, Sakai H, Maruyama T, Otagiri M.

    J Pharm Sci. 106 ( 9 ) 2392 - 2400 2017年

    総説・解説(学術雑誌), 共著

  • Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers.

    Taguchi K, Yamasaki K, Maruyama T, Otagiri M.

    J Funct Biomater. 8 ( 1 ) E11 2017年

    総説・解説(学術雑誌), 共著

  • TDMの落とし穴~偽陽性と偽陰性~.

    田口和明, 猿渡淳二, 平田憲史郎, 丸山徹.

    医療薬学 41 ( 4 ) 215 - 222 2015年

    総説・解説(学術雑誌), 共著

全件表示 >>

競争的資金等の研究課題 【 表示 / 非表示

  • 震災特有疾患に対する一酸化炭素結合型ヘモグロビン小胞体の医薬品としての有用性評価

    2017年04月
    -
    2020年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 田口 和明, 基盤研究(C), 補助金,  代表

受賞 【 表示 / 非表示

  • 熊本大学学長賞

    2011年03月

  • 日本薬学会九州支部学術奨励賞

    2017年12月

 

担当授業科目 【 表示 / 非表示

  • 課題研究(薬効解析学)

    2019年度

  • 演習(薬効解析学)

    2019年度

  • 卒業研究B

    2019年度

  • 卒業研究A

    2019年度

  • 実務実習事前学習1

    2019年度

全件表示 >>